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Abstract The objective of this survey was to assess the beliefs of Swiss psychi-
atrists about the risks associated with cannabis, and to assess their prohibitive
attitudes toward their patients. Eighty-two doctors agreed to fill-up the question-
naire. Cluster analysis retained a 3-cluster solution. Cluster 1: ‘‘Prohibitionists’’
believed that cannabis could induce and trigger all forms of psychiatric disorder,
and showed a highly prohibitive attitude. Cluster 2: ‘‘Causalists’’ believed that
schizophrenia, but not other psychiatric disorders, could be induced and triggered.
Cluster 3: ‘‘Prudent liberals’’ did not believe that psychiatric disorders could be
induced by cannabis, and were generally less prohibitive.
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Introduction
A reappraisal of the traditional narcotic policies is taking place in several European
countries (European Monitoring Centre for Drugs and Drug Addiction (2007).
Cannabis is the drug that has been most discussed in this regard (for example in
Belgium, Italy, Ireland, Luxembourg, Netherlands) and with particularly emotional
political controversies in Switzerland. Whereas the Swiss Senate has twice taken
position in favor of a more liberal drug policy, the House of Representatives has
recently refused to debate the specific amendments to the drug law, which in fact
corresponds to a definitive refusal. In addition, this result has been attributed to a
growingly widespread antidecriminalization sentiment in the population. For
example, several teachers unions have issued statements criticizing decriminaliza-
tion, as have many psychiatrists too. The old debate about the association between
cannabis use and psychosis was reactivated, particularly in the view of the recent
observations of increasing THC concentrations in cannabis products currently found
on the black market, and surveys indicating an increasingly earlier onset of cannabis
use among Swiss children (Muller and Gmel 2002).
For more than a century, physicians’ statements have been very important in
political decisions on drug related issues (Park 1899). Providers’ attitudes regarding
substance use and users may be not only evidence based, but also influenced by their
clinical grade (Carroll 1996), their own consumption habits (Linn et al. 1989) or by
personal ideological and political viewpoints. Attitudes and perceptions of service
delivery highly influence quality of screening and care delivery (Carroll 1995,
1996). Until now, only one previous study has investigated physicians’ attitude
regarding cannabis policies. In that study, 303 GPs, gastroenterologists and
psychiatrists were asked to indicate whether possessing or using marijuana should
be considered a felony, a misdemeanor, warrant the issuance of a citation, or be
legalized (Linn et al. 1989). The position physicians advocated was unrelated to
their specialty, diagnosing experience or method of treating substance abuse
problems, or even to their attitudes toward the efficacy of the treatment of drug
abuse. However, preference for legalization or citation compared to harsher
penalties was more likely to prevail among physicians who were younger, less
religious, politically more liberal, and among those less likely prone to perceive a
serious drug problem in society. Legalization was also more likely favored by
physicians who themselves had used marijuana, cocaine, and amphetamines but was
unrelated to the use of alcohol, cigarettes or tranquilizers. Attitudes of physicians
toward the legalization of marijuana use were not related to the nature of their
practices or clinical experience but rather to personal factors such as using mari-
juana, current attitudes toward drug problem, their religious feelings, and current
political orientations.
As the discussion about the pathogenic properties of cannabis consumption has
increasingly been affected by political debates, scientific findings have been used
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for political arguments and may have often been interpreted according to personal
ideological convictions.
The aim of the present survey was to explore the way psychiatrists evaluate the
risks of cannabis consumption with regard to the induction and the triggering of
psychiatric disorders, and to assess their attitudes towards their patients’ cannabis
consumption. The main study hypothesis was that some psychiatrists’ attitudes
would depend on their patients’ diagnoses, and other psychiatrists’ attitudes would
remain constant and independent of the diagnostic subgroups.
Methods
The present survey was conducted in the context of a 3-day symposium of 103 Swiss
psychiatrists. The symposium was organized and sponsored by the pharmaceutical
company AstraZeneca (Switzerland) on the following themes: Treatment of bipolar
disorders, antipsychotics in elderly patients, acute treatment with antipsychotics and
switching and endocrinological issues in the treatment with antipsychotics.
Physicians in private practice were personally invited by the pharmaceutical
company. Those working in public institutions were formally invited through
invitations sent directly to their institution. Thus, the selection of out of the hospitals
participants was to some degree determined by the pharmaceutical company. The
participants contributed personally to the costs of the symposium (500 CHF & 350 €).
The symposium began with four introductory lectures aiming to stimulate inter-
active discussions during the following workshops. The participants were assigned
to one of the four workshops groups according to their language (one French
speaking and three German speaking). Due to the proportionally low presence of
Italian speaking participants, no Italian-speaking workshop was offered. Instead, the
physicians coming from the Italian speaking part of Switzerland chose to join a
German-speaking group. All speakers and workshops leaders were bilingual (French
and German) in order to guarantee similar conditions in all groups.
Considering the current national political controversy on the cannabis issue and the
opportunity to reach a sample reasonably representative of Swiss psychiatrists, a short 1-
page questionnaire was developed by two of the symposium-speakers (D.Z. and M.P.).
A German and a French version were prepared and controlled for correspondence by
cross-translations. The questionnaire aimed to assess (1) Sociodemographic informa-
tion, (2) The participant’s opinion regarding the risk of cannabis consumption in
inducing different psychiatric disorders, (3) The participant’s belief about the risk of
cannabis consumption in triggering the expression of different psychiatric disorders, and
(4) The participant’s attitude with regard to patients’ possible cannabis consumption.
The questionnaires was distributed preceding one of the workshops (led by H.K.
and D.Z.). Information was given to the participant that his/her participation was
voluntary and anonymous, that the survey was initiated and administered indepen-
dently of the symposium’s sponsor that the objectives of the survey were unrelated to
the purposes and the topics of the symposium and that there was no funding for the
administration of the survey. Also, colleagues interested by this survey were invited
to participate in the analysis of the results and the redaction of the present report.
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Statistics
A hierarchical cluster analysis was performed in SPSS for Windows, version 12.0.
Considering that the measures of all variables included in the cluster analysis were
counts, Chi-square measure was used. Wards clustering algorithm was applied. The
following variables were included in the analysis: the participant’s opinion
regarding the risk of cannabis consumption in inducing different psychiatric
disorders (7 variables, Table 1), the participant’s belief about the risk of cannabis
consumption in triggering the expression of different psychiatric disorders (4
variables, Table 1), and the participant’s attitude with regard to patients’ possible
cannabis consumption (6 variables, Table 2). Clusters were compared with regard to
available sociodemographic data and with regard to the variables, which were
included in the cluster analysis. ANOVA and Pearson’s Chi-square test were
performed when appropriate.
Results
From the 103 physicians attending the symposium, 83 (80.6%) agreed to participate
in the survey. There were missing values for only five items. Only the item ‘‘age’’
was found with an important proportion of missing values, since 21/83 participants
(25.3%) did not reveal their age. One participant did not respond to the four
questions about cannabis possibly inducing psychiatric disorders and was therefore
excluded from the analyses. The mean age of the responders was 42.7 ± 7.9 years
(range 32–62 years). Among the 82 included subjects, 28 (34.1%) were women.
This is in accordance with the nationwide 2002 figure of a percentage of 35%
psychiatrists women (Generalsekretariat 2003). In 2005, 2340 board certified
psychiatrists (37% women) were registered in the Swiss Medical Association FMH
(Foederatio Medicorum Helveticorum 2006), of them 1882 (37% women) had a
private practice. A total of 61 (74.4%) were specialists in psychiatry, 21 (25.6%)
were still in postgraduate training. Seven (8.5%) were residents, 46 (56.1%) were
attendants, 16 (19.5%) head of department or medical director, and 13 (15.9%)
worked in private practice. A total of 53 participants (64.6%) worked in the
German-speaking region, 24 (29.3%) in the French-speaking region, and 5 (6.1%)
in the Italian-speaking region. The corresponding 2002 nationwide figures related
to psychiatric specialists were 65% for the German-speaking psychiatrists, 31.3%
for the French-speaking, and 3.5% for the Italian speaking (Generalsekretariat
2003).
Participants’ Opinion Regarding the Risk of Cannabis Consumption in Inducing
or Triggering Different Psychiatric Disorders
The descriptive statistics regarding participants’ answers on the question are given
in Table 1. Induction or triggering of schizophrenia was thought to happen under
influence of cannabis by over 70% of the respondents. In contrast, only 43% pointed
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to cannabis as potentially inducing manic episodes, all other responses rates were
between 56 and 60%.
Participants’ Attitude with Regard to Patients’ Possible Cannabis Consumption
As reported in Table 2, the sampled psychiatrists were greatly prohibitive with
regard to cannabis consumption in schizophrenic patients, most of them forbidding
the consumption or strongly advising the patient to stop smoking cannabis. Patients
with diseases other than schizophrenia were still often advised not to smoke,
however, psychiatrists attitudes seemed to be less strict. A noteworthy result of
Table 2 is the relatively high proportion (25%) of respondents who would tolerate
cannabis consumption in patients with personality disorder compared to their
attitude related to the other psychiatric disorders.
Comparison of the Clusters
A 3-cluster solution was retained. The characteristics of the three resulting groups of
participants with regard of their beliefs (Table 1) and their attitudes (Table 2) can
be summarized as follows:
Cluster 1
Participants included in this group could be characterized as generally believing that
cannabis could induce and trigger all forms of psychiatric disorders (Table 1), and
showed a highly prohibitive attitude in front of all psychiatric patients (Table 2).
This group was labeled Prohibitionists.
Cluster 2
This group included psychiatrists who mainly believed that the different symptom-
atic dimensions of schizophrenia could be induced and that schizophrenic
manifestations could be triggered by cannabis (Table 1). With regard to the
induction or the triggering of the other disorders, the opinions among this group
were heterogeneously distributed. Whereas their attitude in front of schizophrenic
patients was mostly prohibitive or authoritatively advising, the attitude became
more advisory or tolerant in front of non schizophrenic patients (Table 2). This
group was labeled Causalists.
Cluster 3
This group was composed of psychiatrists who mostly did not believe that cannabis
could induce one of the psychiatric disorders questioned about. However, 71.4% of
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them believed that cannabis could trigger schizophrenic episodes (Table 1).
Whereas they tended to be generally less prohibitive than the participants of the
other two groups, they would mostly advise schizophrenic patients presenting
positive symptoms not to consume cannabis (Table 2). This third group was named
Prudent liberals.
The three clusters were compared with regard to age, sex, language region of
activity, hierarchical position and completed postgraduate training, and no
significant differences were found.
Discussion
The data confirm the initial study hypothesis of different ‘‘prohibition-profiles’’
among Swiss psychiatrists. Attitudes (and even beliefs) of an important part of
Swiss psychiatrists regarding cannabis consumption by psychiatric patients
therefore shows clear resemblances to those found in the population, i.e., a rather
categorical prohibitive or permissive position, indicative more of an ideological
than empirical approach to the cannabis debate. A recent Swiss survey (Institute
Suisse de Prevention de l’Alcoolisme et Autre Toxicomanies 2005) revealed that
among respondents ages 13–29 years asked about the possible effects of cannabis,
responses were dependent on previous or current cannabis consumption. For
example, 59% of current consumers thought that cannabis has relaxing properties
vs. 25% among the never users. On the other hand, 24% of never smokers
considered cannabis to induce addiction, while the proportion was 11% among
current smokers. Interestingly, the result was opposed with regard to the perceived
risk of psychiatric disorders (anxiety, panic attacks, schizophrenia, etc): 9% of never
smokers, 15% of former smokers and 21% of current smokers thought that cannabis
consumption could induce psychiatric disturbances.
In a survey commanded in 1998 by the Swiss Federal Office of Public Health
among the main Swiss actors in the field of harm reduction, 45% of the respondents
representing the cities and the cantons were at least partly favorable to the de-
penalization of cannabis deal and consumption, while in the private and public
institutions, the proportion was 52% (Zobel et al. 1999). An interesting aspect of the
results is the combination of a rather high proportion of responders (80%) and the
high percentage of non-response to the item ‘‘age’’. Whereas participants seemed to
be disposed to give responses of rather delicate political quality, one can assume
that some of them might not have expressed their opinion openly and might have
refused to answer to the question about their age worrying about anonymity. Health
behaviors among doctors have been suggested to be an important marker of how
harmful lifestyle behaviors are perceived. Thus, it has repeatedly been found that
physicians who are smoking restrict from advising their patients to quit smoking
cigarettes (Barengo et al. 2005; Josseran et al. 2005; Nardini et al. 1998; Parna
et al. 2005a, b). Smoking physicians were also less likely to agree with statements
that would change their current freedom to smoke cigarettes (Hodgetts et al. 2004).
Non-smoking physicians had more unfavorable views towards smoking than those
who smoked (Parna et al. 2005b). Former smokers were more likely to indicate that
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their help in getting patients to quit was not effective compared to smokers (Josseran
et al. 2005).
For Swiss physicians, a recent study has revealed some differences compared to
the Swiss population regarding legal substance use. Among the 1784 interviewed
physicians, 12% were current smokers (30% in the general population) and 30%
were at risk alcohol drinkers (15% in the general population) (Sebo et al. 2007). The
prevalence of smokers among Swiss physicians is thus higher than in the USA and
several European countries. The lower smoking prevalence in physicians compared
to the general population confirms, on the other hand, similar figures from various
industrialized countries in North America and Europe (Hughes et al. 1992; Josseran
et al. 2005; La Vecchia et al. 2000; Parna et al. 2005a, b).
The results of this study need to be viewed against their major methodological
limitation. Whereas the interviewed sample of psychiatrists seemed fairly repre-
sentative of Swiss practicing specialists (Generalsekretariat 2003) with regard to sex
and language distribution, there may remain some biasing factors. As the partici-
pants to the symposium were invited by a pharmaceutical company sponsoring the
event, there may have been a particular selection biasing the proportions between
the different belief/attitude clusters.
If policy makers intend to seek physician opinion on the legalization issue, they
have to take into consideration that their opinion may be unrelated to clinical or
scientific credentials. The process of choosing physicians as expert witnesses may
thus prove similar to the process of choosing experts in any field in which facts are
heavily interpreted through surroundings, beliefs, and opinions. When dealing with
controversial moral or ethical issues that may bear on the development or
implementation of legislative policy, physicians behave much like any other group
of citizens.
In conclusion, whereas an evidence-based cannabis-related argumentation is
generally expected from physicians in political discussion, this should not be
considered as granted.
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